Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
25.31
-0.34 (-1.33%)
Nov 6, 2026, 4:00 PM EST - Market closed
Neurogene Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
131
Market Cap
506.49M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 303.73M |
| Valneva SE | 163.30M |
| REGENXBIO | 153.91M |
| Gyre Therapeutics | 110.06M |
| Iambic Therapeutics | 18.25M |
| Capricor Therapeutics | 11.13M |
| SL Science Holding | 3.27M |
NGNE News
- 3 days ago - Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 days ago - Neurogene to Participate in Upcoming Investor Conferences - Business Wire
- 12 days ago - Neurogene presents new data on NGN-401 gene therapy at ESGCT 2026 - TheFly
- 12 days ago - Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome - Business Wire
- 19 days ago - Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress - Business Wire
- 4 weeks ago - Neurogene initiated with an Overweight at JPMorgan - TheFly
- 4 weeks ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Neurogene Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts